Cabot Wealth Management’s Cellectis CLLS Stock Holding History

Cabot Wealth Management’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-31,686	Closed	-$843K	–	150
2016 Q2	$843K	Buy	+31,686	New	+$929K	0.22%	91

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Cabot Wealth Management's CLLS Position: Q3 2016 in Review

Cabot Wealth Management sold out of Cellectis (CLLS) in Q3 2016, closing a stake of 31,686 shares — an estimated $843K sold.

Cabot Wealth Management first reported a position in CLLS in Q2 2016 and held it in 1 quarter. The position peaked at $843K in Q2 2016. 38 funds tracked by Wall St. Rank hold CLLS as of Q3 2016.

Cabot Wealth Management reported no remaining Cellectis position as of Q3 2016 after selling out during the quarter.
Cabot Wealth Management sold 31,686 Cellectis shares in Q3 2016, an estimated $843K.
Cabot Wealth Management first reported a position in Cellectis in Q2 2016 and held it in 1 quarter.
Cabot Wealth Management's Cellectis position peaked at $843K in Q2 2016.
38 funds tracked by Wall St. Rank held Cellectis as of Q3 2016.

Based on Cabot Wealth Management's 13F filing for Q3 2016, filed 8 Nov 2016.